Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN

NCT07627334 | Recruiting

• 1 other identifier: ATTRACTION
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Patients will receive in addition to standard histology analysis also the PDC- based drug screening.

Conditions

Glioblastoma (GBM)

Outcome Measures

Primary Outcomes (1)

• Percentage of patients

  Percentage of patients receiving at least one day of maintenance systemic therapy in the timeframe of 4-6 weeks after completion of a short course radio(-chemo)therapy (40 Gy in 15 fractions)

  From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years

Secondary Outcomes (6)

• PDC-based drug screening

  From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years

• Quality of life assessment

  From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years

• Neurocognitive function

  From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years

• Overall survival

  From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years

• Progression free survival

  From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years

Study Arms (1)

ex vivo drug screening

OTHER

Patients will receive in addition to standard histology analysis also the PDC-based drug screening.

Diagnostic Test: CBmed drug screening platform

Interventions

CBmed drug screening platform DIAGNOSTIC_TEST

The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics

ex vivo drug screening

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• ECOG performance status 0-2
• Newly diagnosed glioblastoma, IDH-wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System
• Unmethylated MGMT promotor per local assessment
• Scheduled short-course radiotherapy with or without concomitant temozolomide
• Written informed consent

You may not qualify if:

• Current participation in another therapeutic clinical trial.
• Patients with a concurrent malignancy or malignancy within five years of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years.
• Pregnant or lactating women.
• Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
• Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥350 cells/mm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended.
• Participants who are unable or unwilling to comply with the requirements of the protocol as assessed by the investigator.

Sponsors & Collaborators

• Medical University of Vienna: lead

Study Sites (1)

AKH Vienna, Department for Internal Medicine I, Oncology

Vienna, State of Vienna, 1090, Austria

RECRUITING

MeSH Terms

Conditions

Glioblastoma

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc.-Prof. PD DDr.

Study Record Dates

• First Submitted: April 9, 2026
• First Posted: June 4, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2029
• Last Updated: June 4, 2026

Record last verified: 2026-05

Locations

AU (1)